Vol. 51 | No. 2 | July-December 2023Back

Open Access

The Management of Atrial Fibrillation in the Philippines: A State-of-the-Art Review

Erdie Fadreguilan
Dec 2023 DOI 10.69944/pjc.4362c3ece7

More Info

Erdie Fadreguilan, MD
Philippine Heart Center

Email for correspondence:
Erdie Fadreguilan, MD
efadreguilan@yahoo.com

References
  1. ​​​Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 2021;16(2):21721. https://doi. org/10.1177/1747493019897870
  2. Chiang CE, Okumura K, Zhang S, Chao TF, Siu C, Lim TW, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythmia 2017. DOI: 10.1016/j.joa.2017.05.004
  3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151 DOI: 10.1056/NEJMoa0905561
  4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891 DOI: 10.1056/NEJMoa1009638
  5. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al for the ARISTOTLE Committee and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992 DOI: 10.1056/NEJMoa1107039
  6. Guigliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Jalperin JL, et al for the ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-2104 DOI: 10.1056/NEJMoa1310907
  7. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al., for the AFFIRM Investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328
  8. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al., for the AFFIRM Investigators. Relationship between sinus rhythm, treatment, and survival in atrial fibrillation follw-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1509-1513
  9. Haissaguerre M, Jais D, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 Sep 3;339(10):659-66. doi: 10.1056/ NEJM199809033391003.
  10. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al., for the CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA 2019;321(13):1261-1274. Doi:10.1001/ jama.2019.0693
  11. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. for the CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378(5);417-427
  12. Kirchhof P, Camm JA, Goette A, Brandes A, Eckardt L, Elvan A, et al., for the EAST-AFNET4 Investrigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383:1305-1316. DOI: 10.1056/ NEJMoa2019422
  13. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al, ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, European Heart Journal Volume 42, Issue 5, 1 February 2021, 373–498 https://doi.org/10.1093/eurheartj/ ehaa612
  14. Ogawa H, An Y, Ikeda S, Aono Y, Doi K, Ishii M, et al. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 2018;49:2301–2308 https://doi.org/10.1161/ STROKEAHA.118.021396
  15. Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Geller L, Kalejs O, et al., for the ATTEST Investigators. Randomized Controlled Atrial Fibrillation Progression. Europace 2021 Mar; 23(3): 362–369a. doi: 10.1093/ europace/euaa298
  16. Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al., for the EARLY-AF Investigators. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med 2023; 388:105-116 DOI: 10.1056/ NEJMoa2212540
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.